YLYi Lu

Yi Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi Lu has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical features and long-term outcomes of patients with ZFYVE19 variants

    by Jia-Qi Li, Yue-Yong Zhu, Mei-Yan Xue, Hao Chi, Xin-Bao Xie, Yi Lu, Jian-She Wang


  • Open Access

    COG6-CDG: Two Novel Variants and Milder Phenotype in a Chinese Patient

    by Xue-Yuan Zhang, Jing Zhang, Yi Lu

    Here, we present a Han Chinese pediatric girl highly suspected of congenial disorder of glycosylation type IIL (CDG2L; OMIM#614576). Her clinical symptoms include transferase abnormal, liver cirrhosis, hemogram, coagulopathy, growth retardation, intellectual disability, frequent infections, and enamel hypoplasia. Trio-genome sequencing identified in COG6 a paternal variant c.1672CT (p.Gln558Ter) and a maternal variant c.153+392AG (p.?). Reverse transcription-polymerase chain reaction (RT-PCR) using mRNA isolated from peripheral blood confirmed the pathogenicity of both variants. The paternal variant resulted in nonsense-mediated mRNA decay. The maternal variant generated two aberrant COG6 transcripts with 154bp overlap and was predicted to result in a frameshift at the same position, leading to generation of a premature termination codon. They might result in synthesis of a truncated form of COG6. Thus, the patient was genetically diagnosed.


  • [A case of primary carnitine deficiency presenting with cholestasis, hepatomegaly, and hyperketonemia].

    by X Y Zhang, J Zhao, Y Lu

    1例7月龄患儿主诉“发现肝大1月,皮肤黄染半月”,主要临床表现为短期进行性肝大、脂肪肝、胆汁淤积、凝血障碍、高氨血症、嗜睡、肌张力低、贫血、高血酮、心肌肥厚、肾小管受损等。血质谱游离肉碱降低,基因测序示SLC22A5基因c.760C>T纯合突变。补充左旋肉碱治疗2个月,肝脏大小及肝功能恢复正常、心肌厚度趋于正常,治疗10个月生长发育趋于正常,肌力改善。

  • Open Access

    Splicing Analysis of MYO5B Noncanonical Variants in Patients with Low Gamma-Glutamyltransferase Cholestasis

    by Li Wang, Yi-Ling Qiu, Kuerbanjiang Abuduxikuer, Neng-Li Wang, Zhong-Die Li, Ye Cheng, Yi Lu, Xin-Bao Xie, Qing-He Xing, Jian-She Wang

    Biallelic MYO5B variants have been associated with familial intrahepatic cholestasis (FIC) with low serum gamma-glutamyltransferase (GGT). Intronic or synonymous variants outside of canonical splice sites (hereinafter referred to as noncanonical variants) with uncertain significance were identified in MYO5B posing a challenge in clinical interpretation. This study is aimed at assessing the effects of these variants on premessenger RNA (pre-mRNA) splicing to improve recognition of pathogenic spliceogenic variants in MYO5B and better characterize the MYO5B genetic variation spectrum. Disease-associated MYO5B noncanonical variants were collected from the literature or newly identified low GGT cholestasis patients. In silico splicing predictions were performed to prioritize potential pathogenic variants. Minigene splicing assays were performed to determine their splicing patterns, with confirmation by blood RNA analysis in one case. Eleven (five novel) noncanonical variants with uncertain significance were identified. Minigene splicing assays revealed that three variants (c.2090+3AT, c.2414+5GT, and c.613-11GA) caused complete aberrations, five variants (c.2349AG/p.(=), c.4221GA/p.(=), c.1322+5GA, c.1669-35AC, and c.3045+3AT) caused predominant aberrations, and three variants (c.4852+11AG, c.455+8TC, and c.2415-6CG) had no effect on pre-mRNA splicing. Patient-derived RNA analysis showed consistent results. Based on our results, eight variants were reclassified as likely pathogenic and three as likely benign. Combining the clinical features and the above analysis, the diagnosis of MYO5B-associated FIC could be made in three new patients. In conclusion, we characterized the splicing patterns of MYO5B noncanonical variants and suggest that RNA analysis should be routinely included in clinical diagnostics to provide essential evidence for the interpretation of variants.

  • Recurrent AKR1D1 c.580-13T>A Variant

    by Jing Zhao, Yi-Ling Qiu, Li Wang, Zhong-Die Li, Xin-Bao Xie, Yi Lu, Kenneth D.R. Setchell, Ye Cheng, Qing-He Xing, Jian-She Wang


  • Defining pathogenicity of NOTCH2 variants for diagnosis of Alagille syndrome type 2 using a large cohort of patients

    by Zhong‐Die Li, Kuerbanjiang Abuduxikuer, Li Wang, Chen‐Zhi Hao, Jing Zhang, Meng‐Xuan Wang, Li‐Ting Li, Yi‐Ling Qiu, Xin‐Bao Xie, Yi Lu, et al.

    Background and Aims: Alagille syndrome (ALGS) type 2 caused by mutations in NOTCH2 has genotypic and phenotypic heterogeneity. Diagnosis in some atypical patients with isolated hepatic presentation could be missed. Methods: Using 2087 patients with paediatric liver manifestations, NOTCH2 allele frequencies, in‐silico prediction, protein domains and clinical features were analysed to define the pathogenicity of NOTCH2 variants for diagnosis of ALGS type 2. Results: Among 2087 patients with paediatric liver manifestations, significantly more NOTCH2 variants were absent in gnomAD in patients with elevated γ‐glutamyltransferase (GGT) ( p = .041). Significantly more NOTCH2 variants which were absent in gnomAD were located in protein functional domains ( p = .038). When missense variants were absent in gnomAD and predicted to be pathogenic by at least three out of seven in‐silico tools, they were found to be significantly associated with liver manifestations with elevated GGT ( p = .003). Comparing this to patients with likely benign (LB) variants, the patients with likely‐pathogenic (LP) variants have significantly more liver manifestations with elevated GGT ( p = .0001). Significantly more patients with LP variants had extra‐hepatic phenotypes of ALGS compared with those patients with LB variants ( p = .0004). Conclusion: When NOTCH2 variants are absent in gnomAD, null variants and missense variants which were predicted to be pathogenic by at least three in‐silico tools could be considered pathogenic in patients with high GGT chronic liver diseases.


  • Open Access

    Poly-hydroxylated bile acids and their prognostic roles in Alagille syndrome

    by Meng-Xuan Wang, Jun Han, Teng Liu, Ren-Xue Wang, Li-Ting Li, Zhong-Die Li, Jun-Cong Yang, Lang-Li Liu, Yi Lu, Xin-Bao Xie, et al.

    The liver manifestations of Alagille syndrome (ALGS) are highly variable, and factors affecting its prognosis are poorly understood. We asked whether or not the composition of bile acids in ALGS patients with good clinical outcomes differs from those with poor outcomes, and whether bile acids could be used as prognostic biomarkers. Blood for bile acid profiling were collected from genetically confirmed JAG1-associated ALGS patients before one year of age. Good prognosis was defined as survival with native liver and total bilirubin (TB) < 85.5 µmol/L, while poor prognosis as either liver transplanted, died of liver failure, or TB ≥ 85.5 µmol/L at last follow-up. We found that the concentrations of two poly-hydroxylated bile acids, tauro-2β,3α,7α,12α-tetrahydroxylated bile acid (THBA), and glyco-hyocholic acid (GHCA), were significantly increased in patients with good prognosis compared to those with poor prognosis (AUC = 0.836 and 0.782, respectively) in the discovery cohort. The same trend was also observed in the molar ratios of GHCA to GCDCA and THCA to TCDCA (both AUC = 0.836). A validation cohort confirmed these findings. Notably, tauro‐2β,3α,7α,12α-THBA achieved the highest prediction accuracy of 88.00% (92.31% sensitivity and 83.33% specificity); GHCA at > 607.69 nmol/L was associated with native liver survival (hazard ratio: 6.456, 95% CI: 1.173–35.545, P = 0.032). We identified two poly-hydroxylated bile acids as the liver prognostic biomarkers of ALGS patients. Enhanced hydroxylation of bile acids may result in better clinical outcomes.

  • Open Access

    Pediatric Wilson disease presenting as acute liver failure: Prognostic indices

    by Wei-Yuan Fang, Kuerbanjiang Abuduxikuer, Peng Shi, Yi-Ling Qiu, Jing Zhao, Yu-Chuan Li, Xue-Yuan Zhang, Neng-Li Wang, Xin-Bao Xie, Yi Lu, et al.

    Acute liver failure (ALF) can be a primary presentation of Wilson disease (WD). Mortality rates are high in WD with ALF (WDALF). Predictions of mortality in WDALF vary by model and are sometimes contradictory, perhaps because few patients are studied or WD diagnoses are questionable. To determine the outcomes among well-documented WDALF patients and assess mortality model performance in this cohort. We reviewed the medical records of our pediatric WDALF patients (n = 41 over 6-years-old, single-center retrospective study) and compared seven prognostic models (King’s College Hospital Criteria, model for end-stage liver disea se/pediatric end-stage liver disease scoring systems, Liver Injury Unit [LIU] using prothrombin time [PT] or international normalized ratio [INR], admission LIU using PT or INR, and Devarbhavi model) with one another. Among the 41 Han Chinese patients with ALF, WD was established by demonstrating ATP7B variants in 36. In 5 others, Kayser-Fleischer rings and Coombs-negative hemolytic anemia permitted diagnosis. Three died during hospitalization and three underwent liver transplantation (LT) within 1 mo of presentation and survived (7.3% each); 35 (85.4%) survived without LT when given enteral D-penicillamine and zinc-salt therapy with or without urgent plasmapheresis. Parameters significantly correlated with mortality included encephalopathy, coagulopathy, and gamma-glutamyl transpeptidase activity, bilirubin, ammonia, and serum sodium levels. Area under the receiver operating curves varied among seven prognostic models from 0.981 to 0.748 with positive predictive values from 0.214 to 0.429. WDALF children can survive and recover without LT when given D-peni cillamine and Zn with or without plasmapheresis, even after enlisting for LT.


  • [An updated advance of autoimmune hepatitis in children].

    by Y Lu

    Autoimmune liver disease is not common in children. In addition to autoimmune hepatitis, it also includes autoimmune sclerosing cholangitis, Giant cell hepatitis with autoimmune hemolytic anemia, and de novo autoimmune hepatitis after liver transplantation as well as two acquired autoimmune liver diseases: neonatal lupus and Gestational alloimmune liver disease (alternate name neonatal hemochromatosis). The age-specific systemic developmental characteristics and immune system association determine the type of autoimmune liver disease in children, and its clinical manifestations and prognostic transition may vary from adults. Here, we discuss the rising clinical incidence of autoimmune hepatitis in children.